Claims
- 1. A compound of formula I′in, whichR1, R2 each independently of one another are H, A, —(CH2)n—Ar or alkenyl having 2 to 6 atoms, R1 and R2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms, Z is CF3, NO2, Hal, OH, NH2, NHA or NA2, A is alkyl having 1 to 6 C atoms, Ar is phenyl which is mono- or disubstituted by Z, Hal is F, Cl, Br or I, n is 1 or 2 or a physiologically acceptable salt or solvate thereof.
- 2. A method for treating a disorder of the central nervous system, comprising administering an effective amount of a compound of formula I to a patient in need thereof in, whichR1, R2 each independently of one another are H, A, —(CH2)n—Ar or alkenyl having 2 to 6 atoms, R1 and R2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms, Z is H, A, CF3, NO2, Hal, OH, NH2, NHA or NA2, A is alkyl having 1 to 6 C atoms, Ar is phenyl which is mono- or disubstituted by Z, Hal is F, Cl, Br or I, n is 1 or 2.
- 3. A method for the treatment of psychoses, schizophrenia, manic depression, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, bulimia, anorexia nervosa, eating disorders, compulsive acts or premenstrual syndrome, comprising administering an effective amount of a compound of formula I to patient in need thereof in, whichR1, R2 each independently of one another are H, A, —(CH2)n—Ar or alkenyl having 2 to 6 atoms, R1 and R2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms, Z is H, A, CF3, NO2, Hal, OH, NH2, NHA or NA2, A is alkyl having 1 to 6 C atoms, Ar is phenyl which is mono- or disubstituted by Z, Hal is F, Cl, Br or I, n is 1 or 2.
- 4. A pharmaceutical composition, comprising a compound of formula I in, whichR1, R2 each independently of one another are H, A, —(CH2)n—Ar or alkenyl having 2 to 6 atoms, R1 and R2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms, Z is H, A, CF3, NO2, Hal, OH, NH2, NHA or NA2, A is alkyl having 1 to 6 C atoms, Ar is phenyl which is mono- or disubstituted by Z, Hal is F, Cl, Br or I, n is 1 or 2 and a pharmaceutically acceptable carrier.
- 5. A process for the production of a pharmaceutical composition according to claim 4, comprising bringing a compound of the formula I or one of its physiologically tolerable salts or solvates into a suitable dose form together with at least one solid, liquid or semiliquid vehicle or excipient and, optionally, one or more other active compounds.
- 6. A method for treating a disease mediated by 5-HT6 receptors, comprising administering an effective amount of a compound of formula I to patient in need thereof in, whichR1, R2 each independently of one another are H, A, —(CH2)n—Ar or alkenyl having 2 to 6 atoms, R1 and R2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms, Z is H, CF3, NO2, Hal, OH, NH2, NHA or NA2, A is alkyl having 1 to 6 C atoms, Ar phenyl which is mono- or disubstituted by Z, Hal is F, Cl, Br or I, n is 1 or 2.
- 7. A method according to claim 6, comprising administeringa) dimethyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-yl]amine, b) [2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)oxazol-5-yl]dimethylamine, c) benzyl-[4-(4-cholorbenzenesulfonyl)-2-(2-chlorophenyl)oxazol-5-yl]amine, d) (4-benzenesulfonyl-2-o-tolyloxazol-5-yl)-methylamine, e) benzyl-[2-(2,4dichlorophenyl)-4-(toluene-4-sulfonyl)oxazol-5-yl]amine, f) [4-benzenusulfonyl-2-(2-,4dichlorophenyl)oxazol-5-yl]benzylamine, or g) [4-benzenusulfonyl-2-(2-,4dichlorophenyl)oxazol-5-yl]dimethylamine.
Priority Claims (1)
Number |
Date |
Country |
Kind |
198 58 593 |
Dec 1998 |
DE |
|
Parent Case Info
This application is a 371 of PCT/EP99/09335 filed on Dec. 1, 1999.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/EP99/09335 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/37452 |
6/29/2000 |
WO |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
9729747 |
Aug 1997 |
WO |
Non-Patent Literature Citations (3)
Entry |
Chervoni et al Ukr. Khim. Zh. (Russ. Ed.) 1991, 57 (4), 415-18 CAS Abstract.* |
Chemical Abstracts vol. 118 No. 125087 (Mar. 2, 1993) abstract No. 124426 p. 798. |
Chervonyi, V.A. et al: “Cyclocondensation of N-(1-arylsulfo-1,2,3-dichlorethynyl)amides of carbonic acids with amines and sodium hyrosulfide” UKR.KHIM.ZH. vol. 57 No. 4 1991. |